Tamiflu also known as oseltamivir phosphate is a drug to prevent and treat influenza virus infections. It is needed to treat severe influenza A and B and also swine flu among patients whose age is two weeks or more and for those whose signs of flu did not last for two days or more. Tamiflu helps in blocking the release of the virus from the infected cells. It is a type of antiviral agent which can be found in capsule form and also in oral suspension.
Globally, the market of Tamiflu is projected to be priced at US$ 889.2 Mn in the year 2022 and is anticipated to show a CAGR of 1.2% in the predicted period from 2022 to 2030.
The growth of the market of Tamiflu is anticipated to rise in the predicted period. This is owing to rising incidence of influenza that happens recurrently across the world, and also the demand of Tamiflu rose up at the time of COVID-19 pandemic, since it has fewer side effects. Furthermore, the majority of the pharmaceutical companies are introducing the standard form of Tamiflu i.e., oseltamivir phosphate, which pushes the market growth, in the predicted period.
Get a comprehensive report summary that describes the Market value and forecast along with methodology.
Request a Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/5489
Tamiflu is directed in treating influenza A, influenza B and Swine Flu (H1N1 influenza). The rising incidence of influenza, across the world, is predicted to raise the market growth of Tamiflu worldwide, in the predicted period. For example, as per an article issued by WHO (World Health Organization) in November 2021, in 2020, the incidence of influenza worldwide was 3 Mn to 5Mn acute cases of illness.
Furthermore, in October 2022, as per CDC’s (Center for Disease Control and Prevention) issue of the rates of incidence in percentage (%) for the recurrent influenza in the seasons of 2017-2018, 2018-2019, 2019-2020 of all age groups in the United States.
Amongst the regions, North America is anticipated to control the market in the predicted period. This is credited owing to the North America’s held of 34.6% share of the market and rise in deficit of Tamiflu for the coming season of influenza in the region of North America. For example, the U.S government on 21st December, 2022, pronounced that the Department of Health and Human Services (HHS) in the U.S. in partnership with Administrationfor Strategic Preparedness and Response (ASPR), does better supplier of extra Tamiflu existing in response of a rise in need for antiviral in the flu season of 2022. This was attained by Strategic National Stockpile (SNS). The government will be working with the regional teams of ASPR to assess the Tamiflu requests by means of SNS. Thereby safeguarding that states, territories and other tribes will get the needed help they require without hampering the country’s readiness for a pandemic that may occur in the future.
The region of Europe is anticipated to rank second as the largest region in the predicted period, owing to rising incidence of the recurrent influenza of the seasons in Europe. For example, as per the ECDC 2022 (European Centre for Disease Prevention and Control), expected that the influenza occurring during the seasons results in causing 4 to 5 Mn infections with symptoms in the EU (European Union) each year and 15,000 to 7,000 citizens in Europe die as the cause in relation to influenza.
The pandemic of Covid-19 is anticipated to hinder the market growth of Tamiflu (Oseltamivir Phosphate), also known as oseltamivir phosphate, worldwide due to the lockdown at the time of the pandemic of COVID-19. The pandemic of coronavirus or COVID-19 and the lockdowns led by the government of every country across the world have affected the financial condition of many business enterprises in all the sectors. The major hit was faced by the private healthcare sector. The pandemic of COVID-19 generated economic problems in the healthcare sectors of many countries. As per Indian Journal of Medical Sciences issued a report in 2020, which claims that the pandemic impacted performing many medical trials owing to the absence of staffs at the trial site, restricted travelling, availability of investigational product and many others.
As per NCBI (National Center for Biotechnology Information) issued a report on 29th April, 2020, that much medical/clinical trial got cancelled or postponed to reduce the risk of getting affected by the deadly coronavirus of the COVID-19 and it caused delay in activating the new medical trials. Furthermore, companies fail to meet the follow-up expectations for the patients which were lined up for trial. Development of product has witnessed interruption in adjusting to work remotely in different environments and the capacity of the laboratories was reduced. Clinical trials got impacted by disturbances of the pandemic in new enrollments as well as in maintaining the existing patients on treatments. As per clinicaltrial.gov, till April 2020, over 2,850 trials and about 900,000 patients were admitted at the trial sites facing partial region lockdown or complete lockdown owing to restrictions of the pandemic. At present, the research and the development laboratories are working at a lower of 50% of the normal capacity worldwide. Majority of the research centers have stopped new trials and also the studies of the in-patients. Diverse pharmaceutical companies have come to the conclusion of delaying the initiation of new medical trials, postponed admission of some trials and have suspended the start of new sites, if any enrollment of trial is continued.
Limited Period Offer | Report Available Now at UP TO 45% off Discounted Pricing @
Single User License : https://www.coherentmarketinsights.com/promo/buynow/5489
Multi Users License : https://www.coherentmarketinsights.com/promo/buynow/5489
Corporate Users License : https://www.coherentmarketinsights.com/promo/buynow/5489
Note: Special discounted pricing is only applicable for direct purchase through website. In case of customization, discount would be subject to scope and coverage of the report.
Globally, the market report of Tamiflu, also known as osetamivir phosphate, worldwide is divided into Drug Type, Indication, Dosage Form, and Distribution Channel.
On the basis of type of drug, the market is divided into branded and generic. Amongst whih, the segment of generic is anticipated to control the market of Tamiflu in the predicted period and this is credited owing to high need of Tamiflu, for treating the recurrent influenza occurring at different seasons.
On the basis of dosage form, the market is divided into Capsules and Suspension. Amongst which, the market of capsule is anticipated to control the market in the predicted period and this is credited owing to capsules’ preference for treating influenza. Furthermore, oral suspension is liked only the patient is not able to swallow capsules.
On the basis of Indication, the market of Tamiflu is divided into Influenza A, Influenza B, and Swine Flu (H1N1 Influenza A). The segment of Influenza a is anticipated to control the market in the predicted period and this is accredited to the higher incidence of rate of Influenza A over other indications.
On the basis of distribution channel, the market of Tamiflu is divided into hospital pharmacies, online pharmacies and retail pharmacies. Amongst which, the segment of hospital pharmacy is anticipated to control the market in the predicted period and this is credited to the rise in number of hospital pharmacies.
Amongst all the segmentation, the segment of drug type leads high in terms of potentiality owing to high need of Tamiflu products. Thus, the maximum manufacturers like NATCO Pharma Limited, Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Teva Pharmaceuticals, and others are producing Tamiflu in generic forms.
Global Tamiflu (Oseltamivir Phosphate) Market Cross Sectional Analysis_MI
In the segment of distribution channel, the segment of hospital pharmacies holds a dominating position in the region of North America owing to the rising number of hospital pharmacies. For example, as per data given by the National Association of Pharmacy Regulatory Authorities in January 2022, the total number of pharmacies in Canada was 11,814 up till January 2022.
In the segment of dosage form, the sub-0segment capsule is dominating North American region owing to the rising number of the elderly (geriatric) population. For example, Lupin Pharmaceuticals is a pharmaceutical company which in February 2018 introduced a standard version of Tamiflu capsules. Lupin Pharmaceuticals holds the fifth position to get the US FDA consent for a Tamiflu standard/generic version.
Global Tamiflu (Oseltamivir Phosphate) Market: Key Developments_MI
Genetech, Inc. is a U.S. Biotechnology Corporation, which announced on 7th December, 2022, that Tamiflu can be availed in U.S. for the distributors in shipping the drugs to U.S. pharmacies which will enhance the clientele base of the drug and this is anticipated to raise the market growth in the predicted period.
Sun Pharmaceutical Industries is a pharmaceutical company which in December 2021 established a novel manufacturing facility in Andhra Pradesh, India. This is anticipated to raise the generic drugs production, which includes drugs for treating influenza, which will boost the market growth, in the predicted period.
Click Here to Request Customization of this Research Report :
Teva Pharmaceutical Industries Ltd. is a pharmaceutical company who in July 2020 made its appearance in the market of Japan, by entering into a joint venture with another pharmaceutical company named Takeda Pharmaceutical Company, announcing plans with new strategies for local operations to be done on a commercial ground. The new strategy emphasizes on marketing generic drugs in the market of Japan that includes generic version of Tamiflu tablets. This is a strategy for expansion anticipated to boost the market growth in the predicted period.
The main factors that can hinder the market of Tamiflu and its growth across the world in the predicted period are product after effects, product recall, and others. For example, Lupin Pharmaceutical Inc, is a pharmaceutical company which in 2021, recalled a single lot of Tamiflu for the purpose of oral suspension. The recall was started after the United Stated Foods and Drug Administration enforcement report, when detection of impurity in the oral suspension.
The main companies participating in the market of Tamiflu (oseltamivir phosphate)worldwide are F.Hoffmann-La Roche Ltd., NATCO Pharma Limited, Teva Pharmaceutical Industries Ltd., LUPIN Limited, Amneal Pharmaceuticals LLC, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Mylan N.V., and Hetero Group.
Contact Us :
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States.